Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. We are advancing two Phase 3 ready therapeutics, VAL-083, a "first-in-class” small-molecule DNA targeting agent with a novel mechanism of action and demonstrated clinical activity against a range of cancers, and REM-001, our photodynamic therapy for Cutaneous Metastatic Breast Cancer (CMBC). Kintara has been enrolling all three Glioblastoma Multiforme (GBM) patient subtypes in the GBM AGILE registrational study since January 2021 with plans to initiate our CMBC confirmatory study mid-2022.